智飞生物撤回儿童型四价流感病毒裂解疫苗和流感病毒裂解疫苗注册申请

Core Viewpoint - The company, Zhifei Biological, announced the withdrawal of its registration applications for the pediatric quadrivalent influenza virus split vaccine and the influenza virus split vaccine due to the need for more comprehensive evaluation of clinical efficacy and market demand for high-quality pediatric vaccines [1] Group 1: Company Actions - Zhifei Biological's subsidiary, Anhui Zhifei Longkema Biological Pharmaceutical Co., Ltd., received a termination notice from the National Medical Products Administration regarding the drug registration applications [1] - The decision to withdraw the applications was made after careful assessment of the vaccine's clinical use effects and the unique characteristics of the immune systems in children [1] - The company plans to continue supplementary research and improve the clinical evidence chain while advancing the listing application process [1]